Choline Alfoscerate products keep growing despite controversy
Approximately 75 billion won in 1Q, up 4% YoY 500 million won gap between Gliatamin and Chongkundang Gliatirin
Choline Alfoscerate products, which have been suffering from difficulties such as clinical re-evaluation due to their efficacy, maintained their growth despite the confusion.
The market size of Choline Alfoscerate in 1Q was 75 billion won, up 4% YoY, according to IQVIA.
Many of the medium-large products with quarterly sales of 1 to 3 billion won showed double-digit growth.
Gliatamin (Daewoong Bio), which leads the market, saw its growth decline.
Gliatamin’s 1Q sales fell 1.4% YoY to 14.9 billion won, down 1.4% YoY, and the gap with Gliatirin (Chong Kun Dang Pharmaceutical), which grew 6.5% to 14.4 billion won during the same period, has narrowed to 500 million won.
Followed by the leaders, Alfocholine (Daewon Pharmaceutical) rose 12.7% to 3 billion won, while Alfoatilin (Yuhan Corporation), which had sales of 3 billion won in 1Q of last year, fell 11.7% and retreated from the 3 billion won mark.
Gria (Korea Prime Pharm) and Glisate (Celltrion Pharm) posted sales of 2.7 billion mark at a growth rate of around 13%.
Moreover, Silvercerin (HUTECS Korea) grew 26.7% from 2 billion won to 2.5 billion won, and Choliatin (Korea Arlico Pharm) reached 2 billion won mark by 2.2 billion won with 25% growth.
Cholrilin (Withus Pharmaceutical) and Cholinate (Hanmi Pharmaceutical) rose alongside to 1.7 billion won mark by growing 36.36% and 23.03%.
Glitin (Jeil Pharmaceutical), Newtirine (Samjin Pharmaceutical), and Alfotin (Kyung Dong Pharm.) have maintained the same levels, while Choliacen (Kolmar Pharma) advanced 7% to 1.1 billion won.